It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The importance of gut microbiota in human health and pathophysiology is undisputable. Despite the abundance of metagenomics data, the functional dynamics of gut microbiota in human health and disease remain elusive. Urolithin A (UroA), a major microbial metabolite derived from polyphenolics of berries and pomegranate fruits displays anti-inflammatory, anti-oxidative, and anti-ageing activities. Here, we show that UroA and its potent synthetic analogue (UAS03) significantly enhance gut barrier function and inhibit unwarranted inflammation. We demonstrate that UroA and UAS03 exert their barrier functions through activation of aryl hydrocarbon receptor (AhR)- nuclear factor erythroid 2–related factor 2 (Nrf2)-dependent pathways to upregulate epithelial tight junction proteins. Importantly, treatment with these compounds attenuated colitis in pre-clinical models by remedying barrier dysfunction in addition to anti-inflammatory activities. Cumulatively, the results highlight how microbial metabolites provide two-pronged beneficial activities at gut epithelium by enhancing barrier functions and reducing inflammation to protect from colonic diseases.
Urolithins are microbial metabolites derived from food polyphenols. Here, Singh et al. show that urolithin A and a synthetic analogue enhance gut barrier function via Nrf2-dependent pathways and mitigate inflammation and colitis in mice, highlighting a potential application for inflammatory bowel diseases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Louisville, Department of Microbiology and Immunology, James Graham Brown Cancer Center, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622)
2 Institute for Stem Cell Biology and Regenerative Medicine (inStem), GKVK campus, Bangalore, India (GRID:grid.413008.e) (ISNI:0000 0004 1765 8271)
3 Centre for Cellular and Molecular Platforms (C-CAMP), GKVK campus, Bangalore, India (GRID:grid.413008.e) (ISNI:0000 0004 1765 8271)
4 University of Toledo College of Medicine and Life Sciences, Department of Physiology and Pharmacology, Toledo, USA (GRID:grid.267337.4) (ISNI:0000 0001 2184 944X)
5 Dalhousie University, Department of Pharmacology, Halifax, Canada (GRID:grid.55602.34) (ISNI:0000 0004 1936 8200)
6 University of Louisville, Computer Engineering and Computer Science, Kentucky Biomedical Research Infrastructure Network, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622)
7 University of Louisville, Department of Medicine, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622)
8 University of Louisville, Department of Pathology, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622)